← Russell 3000 cross-section

INGN Inogen Inc

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$148m
Revenue TTM
$304m
Net income TTM
$-25m
Free cash flow
$-5m
Composite score
53.0
Sector rank
#2970

Valuation

P / E
EV / EBITDA
EV / sales
0.1
FCF yield
-3.36%
Earnings yield vs 10-yr
-21.34pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-8.1%
EBITDA margin
-3.6%
ROE
-14.1%
ROIC
-44.5%
Revenue growth
5.1%

Insider activity, last 90 days

Net open-market
$-0.14m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We are also pursuing geographic expansion, particularly in Europe and other international markets, supported by our distribution network and manufacturing relationships. Results of operations Comparison of three months ended June 30, 2026 and 2025 Revenue Sales revenue increased $4.4 million, or 5.5%, for the three months ended June 30, 2026 from the three months ended June 30, 2025. The increase was primarily attributable to higher demand in our international markets as well as the favorable impact of foreign exchange rates, partially offset by channel mix within the U.S. …Inogen Inc, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →